Objective: Sleep disturbance is a major consequence of hot flashes among breast cancer survivors. This study evaluated the effects of electro-acupuncture (EA) versus gabapentin (GP) for sleep disturbances among breast cancer survivors experiencing daily hot flashes.
H ot flashes are one of the most common and disruptive side effects experienced by breast cancer survivors. 1, 2 Studies suggest that approximately 30% to 40% of women with breast cancer report persistent moderate-to-severe hot flashes. 3, 4 Although precise definitions vary, hot flashes, or flushes, are episodic periods of intense heat beginning at the chest but moving to the neck and face, causing flushing, sweating, and heart palpitations, and lasting several seconds to minutes. 5 Compared with women who undergo natural menopause, breast cancer survivors are at greater risk of experiencing problematic hot flashes for a number of reasons including, but not limited to, age at diagnosis, premature menopause resulting from chemotherapy and surgery, and estrogen deficiency caused by the use of hormonal treatments such as tamoxifen and aromatase inhibitors. 6 Projections suggest that there will be approximately 6 million breast cancer survivors in the United States by the year 2020, 7 making symptom reduction and maintenance of quality of life a clinical priority.
Hot flashes can occur frequently throughout a 24-hour period; however, nocturnal hot flashes are among the most problematic because they can contribute to poor sleep. 8 The construct of poor sleep is multifaceted and can be characterized by insufficient sleep quantity and/or quantity, difficulty falling asleep or staying asleep, and/or nonrestorative sleep. These can be singular symptoms but when combined they represent insomnia disorder, a more severe and pernicious condition. 9 In one of the few studies to objectively measure hot flash frequency using 24-hour skin conductance monitoring in 21 postmenopausal breast cancer survivors, approximately 50% exhibited three to seven nocturnal hot flashes. 10 In a population-based cohort study of 255 midlife women undergoing natural menopause, women who experienced moderate-to-severe hot flashes were 1.8 times more likely to experience poor sleep than women who experience mild or no hot flashes. 11 Hot flash frequency and severity in breast cancer survivors and healthy postmenopausal women have been associated with subjective and objective sleep disturbance, daytime fatigue, mood disturbances, and greater perceived interference with daily life activities. [12] [13] [14] In a longitudinal study of 58 women receiving adjuvant treatment for breast cancer by Savard et al, 15 hot flashes played a significant role in the development and worsening of insomnia symptoms. Considering that disrupted sleep has been associated with poorer overall psychological and physical health outcomes, [16] [17] [18] [19] effective interventions for disruptive nocturnal hot flashes will likely also improve sleep and a host of other downstream concerns.
Studies evaluating medication usage for sleep disturbances related to hot flashes in postmenopausal women indicate safety and effectiveness for drugs such as gabapentin (GP) and venlafaxine. [20] [21] [22] [23] However, women often choose to discontinue these medications due to side effects including dizziness/unsteadiness, fatigue/somnolence, and ataxia when taking GP, and dry mouth, constipation, and headaches with venlafaxine, which, although often mild, are still undesirable. 20, 22, 24 Several recent trials have shown that acupuncture, a therapy originating from Traditional Chinese Medicine, is an effective treatment for hot flashes in breast cancer survivors with few, if any, side effects. [25] [26] [27] [28] [29] Compared with shamacupuncture and no treatment control groups, acupuncture demonstrated a clear improvement in hot flash frequency in a double blind randomized controlled trial of 94 women posttreatment for breast cancer. 30 Acupuncture has also been shown to be more effective than self-care alone for reducing hot flash frequency and intensity, an effect that was maintained at the 12-month follow-up assessment. 31, 32 The effectiveness of acupuncture compared with enhanced self-care was recently confirmed in a large pragmatic randomized controlled trial of 190 women with hot flashes secondary to breast cancer treatment. 33 Several of the above trials also reported improved sleep as a secondary outcome. 25, 26, 30, 31 However, rigorously conducted trials with larger sample sizes and the inclusion of active comparison interventions are required before making definitive statements about the efficacy of acupuncture in improving sleep disturbance related to hot flashes.
Although sleep is often a secondary outcome in interventions for hot flashes, little is known about the comparative effects of acupuncture to pharmacological interventions for sleep disturbances in women with hot flashes. We analyzed prespecified secondary sleep outcomes in a recently completed phase II four-arm randomized controlled trial to evaluate the short-term effects of electro-acupuncture (EA) compared with daily GP, sham acupuncture, and placebo pill in women with breast cancer experiencing bothersome hot flashes. 34 We chose EA in particular because it has been shown to affect endorphins and other central neuropeptides offering biological plausibility for addressing hot flashes. 35 We restricted the analyses to the two active treatment arms (EA and GP) to estimate the related effects of EA to an established pharmacological intervention on sleep quality in women who experience hot flashes. As a secondary aim, we also explored how acupuncture and GP may impact sleep quality in specific domains. Comparative effectiveness research is an identified priority to assist in patient decision-making between available treatment options. 36 
METHODS

Participants
Participants were recruited from November 2009 through June 2013 by physician referral or in-person clinic recruitment at the Abramson Cancer Center of the Hospital of the University of Pennsylvania, an academic medical center in Philadelphia. Eligible participants were women with a history of early stage breast cancer (stages 0-III), free of cancer as determined by an oncologist or primary care physician, with at least two hot flashes daily over the 7-day screening period. Hot flashes had to have been present for at least a month before study entry, and women had to be willing to use nonhormonal contraceptives during the duration of the study if premenopausal. We excluded individuals who had metastatic (stage IV) breast cancer; were currently in active treatment; had initiated or changed hormonal adjuvant therapy within the past 4 weeks or planned to initiate or change hormonal treatment in the coming 14 weeks; were pregnant or breast feeding; had a bleeding disorder or used warfarin/ heparin; had an allergy to or prior use of GP for hot flashes; were currently using an anticonvulsant; or had documented renal failure in the last 12 months. Participants were randomly assigned to treatment groups using computer-generated numbers sealed in opaque envelopes. Randomization was stratified by hormonal therapy status and included random block sizes of four or eight. All participants provided informed consent before randomization. The acupuncture treatments were delivered at medical clinics in the hospital. The Institutional Review Board of the University of Pennsylvania approved the study protocol.
Interventions
EA: Two licensed nonphysician acupuncturists with 8 and 20 years of experience, respectively, administered interventions twice a week for 2 weeks, then weekly for six more weeks, for a total of 10 treatments over 8 weeks. The detailed protocol has been previously published. 34 In brief, for EA, the acupuncturist chose standard points depending on the participant's preferred positions. In addition, up to four acupuncture points were chosen based on the participant's other presenting symptoms (eg, fatigue, insomnia). The needles (30 or 40 mm and 0.25 mm gauge; Seirin-America Inc, Weymouth, MA) GARLAND ET AL were inserted and manipulated until the participant reported ''De Qi'' (sensation of soreness, tingling, etc). 37 A bilateral 2 Hz current was connected between two acupuncture points using a transcutaneous electrical nerve simulation unit. The needles were left in place for 30 minutes with brief manipulation at the beginning, middle, and end of therapy.
GP: A total daily dose of 900 mg was chosen for GP as it was previously found to be effective in a prior placebo controlled trial in breast cancer survivors. 5 There was a 6-day titration phase when participants took one pill (300 mg) at bedtime for 3 days, then twice daily for 3 days, and then three times daily for the remaining 50 days (a total of 8 wks). At the beginning of week 9, the participants tapered the medication by taking one 300 mg pill twice daily for 3 days and once daily for 3 days before discontinuing. The Investigational Drug Services at the University of Pennsylvania purchased GP 300 mg pills and masked the medication by placing the whole intact dose into a larger opaque gelatin capsule shell.
Outcome measures
Sleep disturbance was assessed using the Pittsburgh Sleep Quality Index (PSQI) pre-and posttreatment. The 19-item PSQI instrument produces a global sleep quality score and seven specific component scores: quality, latency, duration, disturbance, habitual sleep efficiency, use of sleeping medications, and daytime dysfunction. Global scores range from 0 to 21 with higher scores indicating poor sleep quality and high sleep disturbance. 38 The hot flash composite score (HFCS) is the weekly average of hot flashes reported on their daily hot flash diary 39 for a 1-week period before and after the 8-week study period. Each participant recorded how many hot flashes she experienced each day and how many were mild, moderate, severe, or very severe. The composite score for each day can be calculated by multiplying the number of mild, moderate, severe, or very severe hot flashes by 1, 2, 3, or 4, respectively, and adding the values. The daily hot flash diary is reliable, valid, and responsive to treatment effects.
Statistical analysis
The primary outcome was mean change in the total PSQI score between the two groups from baseline to end of intervention (week 8) between EA and GP. Secondary outcomes include specific PSQI domains. We used descriptive statistics to summarize data on demographics and cancer history variables. We calculated change scores by subtracting the pre-scores from the post-scores for each participant. We analyzed between-and within-group component and total scores on the PQSI for all participants using independent samples and paired t tests. We assessed associations between change on the PSQI total and component scores and the HFCS using Spearman's rank-order correlations to explore differences in mechanism of action of the two interventions. All statistical analyses were two-sided. Statistical significance was set at <0.05 level. Statistical analyses were performed using STATA.
RESULTS
As previously reported, 35 between November 2009 and June 2013, we screened 498 women and randomized 120. Of these participants, 30 were randomized to EA and 28 to GP. All women remained in the study for the 8-week treatment. Among participants, 27 (90.0%) in the EA group received all 10 acupuncture treatments and 21 (75.0%) in the GP group were adherent to medications based on pill count. The primary reason for nonadherence to EA was scheduling and time commitment versus the primary reason for nonadherence to GP was intolerance of drug side effects.
As shown in Table 1 , among all 58 participants, mean age was 51.7 (SD ¼ 8.5) with a range from 31.1 to 75.5 years. The women had been diagnosed with cancer 3.4 AE 3.9 years before study participation. The sample was primarily self-identified as white women (74.1%), with 22.4% describing themselves as black. The majority of the women were married or in a partnered relationship (70.7%). Most of the women (86.0%) were postmenopausal and 63.8% were on hormonal treatments. Approximately all of the women (93.1%) had attended college or above.
Between-group change in sleep
By week 8, women in the EA group compared with the GP group reported significantly better sleep as indicated by the (Fig. 1) . From the PSQI subscales (Table 2) , women in the EA group reported shorter sleep latency (À0.5 vs 0.1; P ¼ 0.041) and higher sleep efficiency (À0.6 vs 0.0; P ¼ 0.05).
Within-group change in specific domains of sleep Compared with baseline, by week 8, EA improved sleep duration, sleep disturbance, sleep latency, daytime dysfunction, sleep efficiency, and sleep quality (P < 0.05 for all), whereas GP improved duration and sleep quality (P < 0.05) (see Table 2 ).
Associations between changes in hot flashes and sleep disturbances
At baseline, 51 (87.9%) of the women met the clinical cutoff of 5 or higher for sleep disturbance. There were no significant baseline differences in sleep disturbances between conditions with 90% of the women in the EA group and 86% of the women in the GP group exceeding the PSQI cutoff. Women in both groups experienced a significant reduction in the HFCS during treatment (EA: 15.5-8.1, D ¼ 7.4; GP: 13.2-
Significant associations were observed between a reduction in hot flash severity/frequency and improved sleep latency and sleep quality for the full sample. A trend was observed for the PSQI total score. When the groups were considered separately, only a trend toward a reduction in hot flash severity/frequency and improved sleep was seen for the indices of sleep disturbance (EA), sleep latency (GP), and sleep quality (EA and GP) (see Table 3 ). GARLAND ET AL DISCUSSION Sleep disturbances are highly prevalent in breast cancer survivors who experience hot flashes. 8 In our sample, approximately 90% of women could be classified as having poor sleep quality at trial initiation. A recent review of the treatment of insomnia in women with menopausal symptoms by Attarian et al 40 gave GP a level B rating, owing to its favorable safety profile, especially if vasomotor symptoms play a large role in contributing to the sleep disturbances. They also recommended head-to-head evaluations among promising treatments. This is the first study to demonstrate that acupuncture is as good as, if not better in some respects than, GP for improving sleep parameters in women with breast cancer. We demonstrated that when compared with a daily dose of 900 mg of GP, an 8-week course of EA resulted in better self-reported overall sleep quality. Specifically, women receiving EA reported were able to fall asleep faster and spent more time in bed sleeping as opposed to lying awake in bed trying to sleep. Our results suggest that EA results in improved sleep in women with hot flashes and might be a viable treatment option in women who do not wish to take medication.
Despite a significant improvement in sleep for the women in the EA group, it should be noted that the mean scores remained above the recommended clinical cutoff for sleep disturbance suggesting opportunities for further refining the intervention to optimize sleep outcomes in this population. Further research may need to examine the efficacy of acupuncture as an adjunctive treatment to another pharmacological or nonpharmacological intervention to achieve more complete symptom relief in women with disturbed sleep and hot flashes.
It is generally believed that hot flashes produce arousals and awakenings from sleep; however, the research on this has not been entirely consistent. 24 It is more likely that the association between sleep and hot flashes is bidirectional. In a controlled laboratory study of 19 symptomatic and asymptomatic post-and premenopausal women between the ages of 46 and 51 years using sleep electroencephalograms and sternal skin conductance to record hot flashes, Freedman and Roehrs 41 found that hot flashes tended to follow rather than precede arousals and awakenings. This means that the women woke up for a reason not related to hot flash activity (eg, normal sleep stage transitions), at which time they experienced the hot flash. This suggests that improving sleep and reducing nocturnal arousals may lead to fewer hot flashes, and similarly, reducing nocturnal hot flashes can improve overall sleep. In our study, the correlations between change in hot flash severity/frequency and sleep outcomes were generally small. The strongest associations (although still approximately 0.30) were observed between a reduction in hot flash severity/frequency and improved sleep quality, regardless of treatment condition. This suggests that other factors may influence the association between sleep quality and hot flash severity/frequency including within-night distribution of hot flashes, disruption caused by severity of sweating (eg, needing to change bed clothes or sheets), and/or the psychological interpretation of distress caused by the awakening and the hot flash. Additional research with larger samples is needed to investigate potential differences in pathways and/or mechanisms of action for both treatments.
It is also not currently understood how exactly acupuncture might beneficially impact hot flash severity/frequency and sleep. Acupuncture has been shown to affect a number of neurotransmitters and hormonal factors associated with sleep, such as serotonin, melatonin, and gamma-aminobutyric acid. 42 Evidence also suggests that acupuncture has the potential to repair fragmented sleep architecture and increase time spent in slow wave sleep, 43 which would correspond to the perception of a deeper and more restorative sleep. A systematic review of 20 randomized controlled trials of acupuncture for insomnia suggested that traditional needle acupuncture was slightly more effective than benzodiazepines with response rates for acupuncture and benzodiazepines being 91% and 75%. 44 Similarly, acupuncture was found to be equally as effective as zolpidem for improving sleep in 33 individuals with insomnia. 45 The search for potential mechanisms of acupuncture is still in the early stages, and work is currently ongoing to help researchers design trials to better understand its effect. 46, 47 Despite several strengths, including two active treatment groups, a well-defined sample, and excellent retention of participants, the following limitations deserve mention. First, there was no follow-up assessment after the end of treatment; therefore, it is not possible to evaluate any potential differences in the long-term effects of acupuncture versus GP on sleep in women with hot flashes. Second, sleep and vasomotor activity were assessed with self-report measures. Although this is standard in comparative trials because it allows for people to be assessed in their own environment, future research may want to include objective and/or in laboratory measurements such as actigraphy, electroencephalograms, and/or skin conductance to better understand the relationship between sleep and hot flashes and the effect of treatment. Third, sleep was a secondary outcome and we did not purposely select the sample for the presence of disturbed sleep or screen for the presence of sleep disorders (eg, insomnia, sleep disordered breathing). This prevents us from specifically defining the nature of the sleep disturbances. Further research is needed to replicate this finding in studies with larger and more diverse samples and follow-up assessments to establish the durability of effect.
CONCLUSIONS
Sleep disturbances, including those that occur in conjunction with hot flashes, are especially problematic because of their negative relationship to psychological health and physical well-being. More often than not, poor sleep increases levels of pain, fatigue, depression, and anxiety, creating a positive feedback loop in which all symptoms are amplified and overall symptom burden is increased. 48, 49 The use of targeted interventions to treat difficulty sleeping and hot flashes would be expected to also positively impact other areas of functioning as well. We have demonstrated that EA produces comparable, if not better, improvements in sleep quality than GP, a currently recommended pharmacological intervention. Comparative effectiveness studies such as this represent a step forward in providing clinicians and participants with information needed to make better and more informed treatment decisions.
